Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-19T05:23:01.329Z Has data issue: false hasContentIssue false
  • English
  • Français

Venlafaxine-clomipramine combination

Published online by Cambridge University Press:  16 April 2020

F Benazzi
F Benazzi*
Affiliation:
Department of Psychiatry, Public Hospital “Morgagni”, 47100Forlì, Italy
*
*Correspondence: Dr franco Benazzi, via Pozzetto 17. 48010 Castiglione di Cervia RA, Italy.

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the editors
Information
European Psychiatry , Volume 12 , Issue 5 , 1997 , pp. 265 - 266
Copyright
Copyright © European Psychiatric Association 1997

References

Baldessarini, RJDrugs and the treatment of psychiatric disorders In: Hardman, JGLimbird, LEMolinoff, PBRuddon, RWGoodman Gillman, A eds. Goodman A Gilman's The Pharmacological Basis of Therapeutics New York: McGraw-Hill, 1996; 399–459Google Scholar
Benazzi F. Urinary retention with venlafaxine — halopcridot combination. Pharmacopsychiatry, in pressGoogle Scholar
Benazzi F. Venlafaxine — fluoxetine — nortriptyline interaction. Submitted for publication, aGoogle Scholar
Benazzi F. Anticholinergic toxic syndrome with venlafaxine — desipramine combination. Submitted for publication, bGoogle Scholar
Ereshefsky, L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 16suppl 21996 37S–53S10.1097/00004714-199606002-00009CrossRefGoogle ScholarPubMed
Nemeroff, CB, Lindsay DeVane, C, Pollock, BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311–320Google ScholarPubMed
Physicians' Desk Reference 50 editionMontvale, NJ: Medical Economics Company, 1996; 2719–2723Google Scholar
Preskorn, SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 54suppl 91993 14–34Google ScholarPubMed
Preskorn, SH. Reducing the risk of drug-drug interactions: a goal of rational drug development. J Clin Psychiatry 57suppl 11996 13–16Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.